New frontier in regenerative medicine: Site-specific gene correction in patient-specific induced pluripotent stem cells

Human Gene Therapy

Volumn 24, Issue 6, 2013, Pages 571-583

  Garate, Zita ^a   Davis, Brian R ^b   Quintana Bustamante, Oscar ^a   Segovia, Jose C ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DEOXYRIBONUCLEASE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENTIVIRUS VECTOR; MEGANUCLEASE; MESSENGER RNA; MICRORNA; RETROVIRUS VECTOR; TAL EFFECTOR NUCLEASE; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; BETA THALASSEMIA; CELL DIFFERENTIATION; CELL RENEWAL; CELL TYPE; EPISOME; GENE LOCUS; GENE MUTATION; GENETIC ENGINEERING; GENOMIC INSTABILITY; HEMATOLOGIC DISEASE; HOMOLOGOUS RECOMBINATION; HUMAN; NONHUMAN; NUCLEAR REPROGRAMMING; PARKINSON DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; RNA EDITING; SAFETY; SENDAI VIRUS; SICKLE CELL ANEMIA; STEM CELL GENE THERAPY; TRANSPOSON;

GENETIC THERAPY; GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; INDUCED PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE;

EID: 84879175140     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.251     Document Type: Review

References (107)

1. Amabile, G., Welner, R.S., Nombela-Arrieta, C., et al. (2013). In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood 121, 1255-1264.
2. An, M.C., Zhang, N., Scott, G., et al. (2012). Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11, 253-263.
3. Anderson, W.F., Blaese, R.M., and Culver, K. (1990). The ADA human gene therapy clinical protocol: Points to consider: Response with clinical protocol, July 6, 1990. Hum. Gene Ther. 1, 331-362.
4. Anokye-Danso, F., Trivedi, C.M., Juhr, D., et al. (2011). Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 8, 376-388.
5. Araki, R., Uda, M., Hoki, Y., et al. (2013). Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 494, 100-104.
6. Ban, H., Nishishita, N., Fusaki, N., et al. (2011). Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc. Natl. Acad. Sci. U.S.A. 108, 14234-14239.
7. Batista, L.F., Pech, M.F., Zhong, F.L., et al. (2011). Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 474, 399-402.
8. Bedel, A., Taillepierre, M., Guyonnet-Duperat, V., et al. (2012). Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors. Am. J. Hum. Genet. 91, 109-121.
9. Belay, E., Matrai, J., Acosta-Sanchez, A., et al. (2010). Novel hyperactive transposons for genetic modification of induced pluripotent and adult stem cells: A nonviral paradigm for coaxed differentiation. Stem Cells 28, 1760-1771.
10. Blasco, M.A., Serrano, M., and Fernandez-Capetillo, O. (2011). Genomic instability in iPS: Time for a break. EMBO J. 30, 991-993.
11. Bock, C., Kiskinis, E., Verstappen, G., et al. (2011). Reference maps of human ES and iPS cell variation enable highthroughput characterization of pluripotent cell lines. Cell 144, 439-452.
12. Carroll, D. (2011). Zinc-finger nucleases: A panoramic view. Curr. Gene Ther. 11, 2-10.
13. Carvajal-Vergara, X., Sevilla, A., D'Souza, S.L., et al. (2010). Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465, 808-812.
14. Cayo, M.A., Cai, J., Delaforest, A., et al. (2012). JD iPS cellderived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia. Hepatology 56, 2163-2171.
15. Chang, C.J., and Bouhassira, E.E. (2012). Zinc-finger nuclease mediated correction of a-thalassemia in iPS cells. Blood 120, 3906-3914.
16. Chin, M.H., Mason, M.J., Xie, W., et al. (2009). Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5, 111-123.
17. Daboussi, F., Zaslavskiy, M., Poirot, L., et al. (2012). Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases. Nucleic Acids Res. 40, 6367-6379.
18. Deans, R.J., and Moseley, A.B. (2000). Mesenchymal stem cells: Biology and potential clinical uses. Exp. Hematol. 28, 875-884.
19. Delacote, F., and Lopez, B.S. (2008). Importance of the cell cycle phase for the choice of the appropriate DSB repair pathway, for genome stability maintenance: The trans-S double-strand break repair model. Cell Cycle 7, 33-38.
20. Deng, J., Shoemaker, R., Xie, B., et al. (2009). Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat. Biotechnol. 27, 353-360.
21. Doi, A., Park, I.H., Wen, B., et al. (2009). Differential methylation of tissue-and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41, 1350-1353.
22. Fischer, A., Hacein-Bey-Abina, S., and Cavazzana-Calvo, M. (2010). 20 years of gene therapy for SCID. Nat. Immunol. 11, 457-460.
23. Fusaki, N., Ban, H., Nishiyama, A., et al. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 85, 348-362.
24. Galli, R., Gritti, A., Bonfanti, L., and Vescovi, A.L. (2003). Neural stem cells: An overview. Circ. Res. 92, 598-608.
25. Ghosh, Z., Wilson, K.D., Wu, Y., et al. (2010). Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells. PLoS One 5, e8975.
26. Gore, A., Li, Z., Fung, H.L., et al. (2011). Somatic coding mutations in human induced pluripotent stem cells. Nature 471, 63-67.
27. Grabarz, A., Barascu, A., Guirouilh-Barbat, J., and Lopez, B.S. (2012). Initiation of DNA double strand break repair: Signaling and single-stranded resection dictate the choice between homologous recombination, non-homologous end-joining and alternative end-joining. Am. J. Cancer Res. 2, 249-268.
28. Guenther, M.G., Frampton, G.M., Soldner, F., et al. (2010). Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell 7, 249-257.
29. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419.
30. Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142.
31. Hanna, J., Wernig, M., Markoulaki, S., et al. (2007). Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318, 1920-1923.
32. Hanna, J., Markoulaki, S., Schorderet, P., et al. (2008). Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 133, 250-264.
33. Hanna, J., Saha, K., Pando, B., et al. (2009). Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 462, 595-601.
34. Hockemeyer, D., Soldner, F., Beard, C., et al. (2009). Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 27, 851-857.
35. Hockemeyer, D., Wang, H., Kiani, S., et al. (2011). Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29, 731-734.
36. Howden, S.E., Gore, A., Li, Z., et al. (2011). Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy. Proc. Natl. Acad. Sci. U.S.A. 108, 6537-6542.
37. Hu, K., Yu, J., Suknuntha, K., et al. (2011). Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood 117, e109-e119.
38. Irion, S., Luche, H., Gadue, P., et al. (2007). Identification and targeting of the ROSA26 locus in human embryonic stem cells. Nat. Biotechnol. 25, 1477-1482.
39. Israel, M.A., Yuan, S.H., Bardy, C., et al. (2012). Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482, 216-220.
40. Jia, F., Wilson, K.D., Sun, N., et al. (2010). A nonviral minicircle vector for deriving human iPS cells. Nat. Methods 7, 197-199.
41. Kaji, K., Norrby, K., Paca, A., et al. (2009). Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458, 771-775.
42. Karumbayaram, S., Novitch, B.G., Patterson, M., et al. (2009). Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells 27, 806-811.
43. Khan, I.F., Hirata, R.K., Wang, P.R., et al. (2010). Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Mol. Ther. 18, 1192-1199.
44. Kim, D., Kim, C.H., Moon, J.I., et al. (2009). Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4, 472-476.
45. Kim, J.B., Zaehres, H., Arauzo-Bravo, M.J., and Scholer, H.R. (2009). Generation of induced pluripotent stem cells from neural stem cells. Nat. Protoc. 4, 1464-1470.
46. Kim, K., Zhao, R., Doi, A., et al. (2011). Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat. Biotechnol. 29, 1117-1119.
47. Kim, K.Y., Hysolli, E., and Park, I.H. (2011). Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc. Natl. Acad. Sci. U.S.A. 108, 14169-14174.
48. Kim, Y.G., Cha, J., and Chandrasegaran, S. (1996). Hybrid restriction enzymes: Zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. U.S.A. 93, 1156-1160.
49. Kumano, K., Arai, S., Hosoi, M., et al. (2012). Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 119, 6234-6242.
50. Kunisato, A., Wakatsuki, M., Shinba, H., et al. (2010). Direct generation of induced pluripotent stem cells from human nonmobilized blood. Stem Cells Dev. 20, 159-168.
51. Li, T., Huang, S., Zhao, X., et al. (2011). Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. Nucleic Acids Res. 39, 6315-6325.
52. Liu, G.H., Suzuki, K., Qu, J., et al. (2011). Targeted gene correction of laminopathy-associated LMNA mutations in patientspecific iPSCs. Cell Stem Cell 8, 688-694.
53. Liu, J., Sumer, H., Leung, J., et al. (2010). Late passage human fibroblasts induced to pluripotency are capable of directed neuronal differentiation. Cell Transplant. 20, 193-203.
54. Liu, T., Zou, G., Gao, Y., et al. (2012). High efficiency of reprogramming CD34+ cells derived from human amniotic fluid into induced pluripotent stem cells with Oct4. Stem Cells Dev. 21, 2322-2332.
55. Lombardo, A., Genovese, P., Beausejour, C.M., et al. (2007). Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25, 1298-1306.
56. Marchetto, M.C., Yeo, G.W., Kainohana, O., et al. (2009). Transcriptional signature and memory retention of humaninduced pluripotent stem cells. PLoS One 4, e7076.
57. Matrai, J., Cantore, A., Bartholomae, C.C., et al. (2011). Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology 53, 1696-1707.
58. Meng, X., Neises, A., Su, R.J., et al. (2012). Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone. Mol. Ther. 20, 408-416.
59. Moretti, A., Bellin, M., Welling, A., et al. (2010). Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl J. Med. 363, 1397-1409.
60. Mussolino, C., Morbitzer, R., Lutge, F., et al. (2011). A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 39, 9283-9293.
61. Newman, A.M., and Cooper, J.B. (2010). Lab-specific gene expression signatures in pluripotent stem cells. Cell Stem Cell 7, 258-262.
62. Ohi, Y., Qin, H., Hong, C., et al. (2011). Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat. Cell Biol. 13, 541-549.
63. Papapetrou, E.P., and Sadelain, M. (2011). Generation of transgenefree human induced pluripotent stem cells with an excisable single polycistronic vector. Nat. Protoc. 6, 1251-1273.
64. Papapetrou, E.P., Lee, G., Malani, N., et al. (2011). Genomic safe harbors permit high b-globin transgene expression in thalassemia induced pluripotent stem cells. Nat. Biotechnol. 29, 73-78.
65. Paques, F., and Duchateau, P. (2007). Meganucleases and DNA double-strand break-induced recombination: Perspectives for gene therapy. Curr. Gene Ther. 7, 49-66.
66. Park, I.H., Arora, N., Huo, H., et al. (2008). Disease-specific induced pluripotent stem cells. Cell 134, 877-886.
67. Pera, M.F. (2011). Stem cells: The dark side of induced pluripotency. Nature 471, 46-47.
68. Porteus, M.H., and Carroll, D. (2005). Gene targeting using zinc finger nucleases. Nat. Biotechnol. 23, 967-973.
69. Ramos-Mejia, V., Montes, R., Bueno, C., et al. (2012). Residual expression of the reprogramming factors prevents differentiation of iPSC generated from human fibroblasts and cord blood CD34+ progenitors. PLoS One 7, e35824.
70. Rashid, S.T., Corbineau, S., Hannan, N., et al. (2010). Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J. Clin. Invest. 120, 3127-3136.
71. Raya, A., Rodriguez-Piza, I., Guenechea, G., et al. (2009). Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460, 53-59.
72. Robbins, J. (1993). Gene targeting: The precise manipulation of the mammalian genome. Circ. Res. 73, 3-9.
73. Sebastiano, V., Maeder, M.L., Angstman, J.F., et al. (2011). In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 29, 1717-1726.
74. Seki, T., Yuasa, S., and Fukuda, K. (2011). Derivation of induced pluripotent stem cells from human peripheral circulating T cells. Curr. Protoc. Stem Cell Biol. Chapter 4, Unit4A 3.
75. Soldner, F., Hockemeyer, D., Beard, C., et al. (2009). Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964-977.
76. Soldner, F., Laganiere, J., Cheng, A.W., et al. (2011). Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146, 318-331.
77. Somers, A., Jean, J.C., Sommer, C.A., et al. (2010). Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 28, 1728-1740.
78. Sommer, C.A., Sommer, A.G., Longmire, T.A., et al. (2010). Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells 28, 64-74.
79. Song, H., Chung, S.K., and Xu, Y. (2010). Modeling disease in human ESCs using an efficient BAC-based homologous recombination system. Cell Stem Cell 6, 80-89.
80. Staerk, J., Dawlaty, M.M., Gao, Q., et al. (2010). Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell 7, 20-24.
81. Sun, N., Panetta, N.J., Gupta, D.M., et al. (2009). Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc. Natl. Acad. Sci. U.S.A. 106, 15720-15725.
82. Sun, N., Yazawa, M., Liu, J., et al. (2012). Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 4, 130ra47.
83. Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676.
84. Takahashi, K., Tanabe, K., Ohnuki, M., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872.
85. Takayama, K., Inamura, M., Kawabata, K., et al. (2012). Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4a transduction. Mol. Ther. 20, 127-137.
86. Tanaka, T., Takahashi, K., Yamane, M., et al. (2012). Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery. Blood.
87. Thier, M., Munst, B., and Edenhofer, F. (2010). Exploring refined conditions for reprogramming cells by recombinant Oct4 protein. Int. J. Dev. Biol. 54, 1713-1721.
88. Thomas, E.D., Fefer, A., Buckner, C.D., and Storb, R. (1977). Current status of bone marrow transplantation for aplastic anemia and acute leukemia. Blood 49, 671-681.
89. Torres, R., Garcia, A., Paya, M., and Ramirez, J.C. (2011). Nonintegrative lentivirus drives high-frequency Cre-mediated cassette exchange in human cells. PLoS One 6, e19794.
90. Valton, J., Daboussi, F., Leduc, S., et al. (2012a). 5- Cytosinephosphoguanine (CpG) methylation impacts the activity of natural and engineered meganucleases. J. Biol. Chem. 287, 30139-30150.
91. Valton, J., Dupuy, A., Daboussi, F., et al. (2012b). Overcoming transcription activator-like effector (TALE) DNA binding domain sensitivity to cytosine methylation. J. Biol. Chem. 287, 38427-38432.
92. Wang, P., Rodriguez, R.T., Wang, J., et al. (2011). Targeting SOX17 in human embryonic stem cells creates unique strategies for isolating and analyzing developing endoderm. Cell Stem Cell 8, 335-346.
93. Wang, Y., Zheng, C.G., Jiang, Y., et al. (2012). Genetic correction of b-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice. Cell Res. 22, 637-648.
94. Warren, L., Manos, P.D., Ahfeldt, T., et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618-630.
95. Woltjen, K., Hamalainen, R., Kibschull, M., et al. (2011). Transgene-free production of pluripotent stem cells using piggyBac transposons. Methods Mol. Biol. 767, 87-103.
96. Yamanaka, S. (2012). Induced pluripotent stem cells: Past, present, and future. Cell Stem Cell 10, 678-684.
97. Yanez-Munoz, R.J., Balaggan, K.S., MacNeil, A., et al. (2006). Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 12, 348-353.
98. Yao, Y., Nashun, B., Zhou, T., et al. (2011). Generation of CD34+ cells from CCR5-disrupted human embryonic and induced pluripotent stem cells. Hum. Gene Ther. 23, 238-242.
99. Yazawa, M., Hsueh, B., Jia, X., et al. (2011). Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471, 230-234.
100. Ye, Z., Zhan, H., Mali, P., et al. (2009). Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 114, 5473-5480.
101. Yu, J., Vodyanik, M.A., Smuga-Otto, K., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920.
102. Yu, J., Hu, K., Smuga-Otto, K., et al. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. Science 324, 797-801.
103. Yui, S., Nakamura, T., Sato, T., et al. (2012). Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5 + stem cell. Nat. Med. 18, 618-623.
104. Yusa, K., Rashid, S.T., Strick-Marchand, H., et al. (2011). Targeted gene correction of a1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478, 391-4.
105. Zhou, W., and Freed, C.R. (2009). Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 27, 2667-2674.
106. Zou, J., Mali, P., Huang, X., et al. (2011a). Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118, 4599-4608.
107. Zou, J., Sweeney, C.L., Chou, B.K., et al. (2011b). Oxidasedeficient neutrophils from X-linked chronic granulomatous disease iPS cells: Functional correction by zinc finger nucleasemediated safe harbor targeting. Blood 117, 5561-5572.